Antibody data
- Antibody Data
- Antigen structure
- References [70]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-11833 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD24 Monoclonal Antibody (SN3b)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- MA5-11833 targets CD24 in WB, ICC/IF, FACS and IHC (P) applications and shows reactivity with Human and Mouse samples. This antibody is not suitable for mouse BAF-3 cell lysates in Western blot analysis. The MA5-11833 immunogen is cell membrane antigen preparation isolated from NALM-1 human pre-B leukemia cell line.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Isotype
- IgM
- Antibody clone number
- SN3b
- Vial size
- 500 µL
- Concentration
- 0.8 mg/mL
- Storage
- 4° C
Submitted references Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways.
The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer.
Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Membranous CD24 drives the epithelial phenotype of pancreatic cancer.
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer.
Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer.
Interleukin-6 and pro inflammatory status in the breast tumor microenvironment.
Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Genetic and phenotypic diversity in breast tumor metastases.
Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy.
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation.
CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma.
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Histological study of stem-like cells in human colon adenocarcinoma at different stages of the disease.
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma.
CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.
Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.
Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
CD24 expression as a marker for predicting clinical outcome in human gliomas.
Clinical value of CD24 expression in retinoblastoma.
Expression of adhesion, attachment and invasion markers in eutopic and ectopic endometrium: a link to the aetiology of endometriosis.
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.
Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Stem cell-related markers in primary breast cancers and associated metastatic lesions.
CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery.
Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.
Identification of prognostic biomarkers for glioblastomas using protein expression profiling.
Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expression.
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.
Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation.
Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin.
Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma.
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients.
CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium.
CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
CD24 expression is a new prognostic marker in breast cancer.
Liao S, Gan L, Qin W, Liu C, Mei Z
Oncology reports 2018 Oct;40(4):2005-2013
Oncology reports 2018 Oct;40(4):2005-2013
The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer.
Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H
Breast cancer (Dove Medical Press) 2016;8:117-24
Breast cancer (Dove Medical Press) 2016;8:117-24
Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, Saito M
PloS one 2016;11(10):e0165253
PloS one 2016;11(10):e0165253
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer E, Letai A, Barry WT, Carroll JS, Long H, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K
Nature 2016 Jan 21;529(7586):413-417
Nature 2016 Jan 21;529(7586):413-417
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Davidson B
Human pathology 2016 Dec;58:123-127
Human pathology 2016 Dec;58:123-127
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Liu YX, Wang KR, Xing H, Zhai XJ, Wang LP, Wang W
Oncology letters 2016 Aug;12(2):1240-1256
Oncology letters 2016 Aug;12(2):1240-1256
Membranous CD24 drives the epithelial phenotype of pancreatic cancer.
Lubeseder-Martellato C, Hidalgo-Sastre A, Hartmann C, Alexandrow K, Kamyabi-Moghaddam Z, Sipos B, Wirth M, Neff F, Reichert M, Heid I, Schneider G, Braren R, Schmid RM, Siveke JT
Oncotarget 2016 Aug 2;7(31):49156-49168
Oncotarget 2016 Aug 2;7(31):49156-49168
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer.
Kwon MJ, Han J, Seo JH, Song K, Jeong HM, Choi JS, Kim YJ, Lee SH, Choi YL, Shin YK
PloS one 2015;10(10):e0139112
PloS one 2015;10(10):e0139112
Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer.
Karakas D, Cevatemre B, Aztopal N, Ari F, Yilmaz VT, Ulukaya E
Bioorganic & medicinal chemistry 2015 Sep 1;23(17):5580-6
Bioorganic & medicinal chemistry 2015 Sep 1;23(17):5580-6
Interleukin-6 and pro inflammatory status in the breast tumor microenvironment.
Sanguinetti A, Santini D, Bonafè M, Taffurelli M, Avenia N
World journal of surgical oncology 2015 Mar 28;13:129
World journal of surgical oncology 2015 Mar 28;13:129
Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML, Thike AA, Tan SY, Tan PH
Breast cancer research and treatment 2015 Feb;150(1):31-41
Breast cancer research and treatment 2015 Feb;150(1):31-41
Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.
Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, Matsuno Y, Taketomi A
BMC cancer 2014 Sep 21;14:687
BMC cancer 2014 Sep 21;14:687
Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse.
Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, Nakopoulou L
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2014 Mar;40(3):289-96
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2014 Mar;40(3):289-96
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K
Oncotarget 2014 Mar 15;5(5):1174-84
Oncotarget 2014 Mar 15;5(5):1174-84
Genetic and phenotypic diversity in breast tumor metastases.
Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K
Cancer research 2014 Mar 1;74(5):1338-48
Cancer research 2014 Mar 1;74(5):1338-48
Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy.
Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, Rigo-Watermeier T, Baccelli I, Vogel V, Trumpp A, Sprick MR
Urologic oncology 2014 Jul;32(5):678-86
Urologic oncology 2014 Jul;32(5):678-86
CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A, Niemiec JA, Ambicka A, Mucha-Małecka A, Mituś J, Ryś J
Journal of molecular histology 2014 Feb;45(1):35-45
Journal of molecular histology 2014 Feb;45(1):35-45
MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM, Kim HJ, Kim EJ, Chung YR, Yun S, Seo AN, Lee HJ, Park SY
Breast cancer research and treatment 2014 Aug;147(1):39-49
Breast cancer research and treatment 2014 Aug;147(1):39-49
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation.
Wang YC, Wang JL, Kong X, Sun TT, Chen HY, Hong J, Fang JY
Apoptosis : an international journal on programmed cell death 2014 Apr;19(4):643-56
Apoptosis : an international journal on programmed cell death 2014 Apr;19(4):643-56
CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Zhou X
Clinical breast cancer 2014 Apr;14(2):e33-40
Clinical breast cancer 2014 Apr;14(2):e33-40
Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.
Wu Y, Sarkissyan M, Elshimali Y, Vadgama JV
PloS one 2013;8(10):e78259
PloS one 2013;8(10):e78259
Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ, Lee KB, Jang JY, Kwon W, Park JW, Chang YR, Kim SW
Pancreas 2013 Nov;42(8):1267-74
Pancreas 2013 Nov;42(8):1267-74
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma.
Pinato DJ, Nya P, Sharma R, Mauri FA
Journal of clinical pathology 2013 Mar;66(3):256-9
Journal of clinical pathology 2013 Mar;66(3):256-9
CD24 expression predicts distant metastasis in extrahepatic bile duct cancer.
Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW
World journal of gastroenterology 2013 Mar 7;19(9):1438-43
World journal of gastroenterology 2013 Mar 7;19(9):1438-43
Histological study of stem-like cells in human colon adenocarcinoma at different stages of the disease.
Florianova L, Orain M, Têtu B, Doillon CJ
Biotechnic & histochemistry : official publication of the Biological Stain Commission 2013 Jul;88(5):222-34
Biotechnic & histochemistry : official publication of the Biological Stain Commission 2013 Jul;88(5):222-34
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL
Breast cancer research and treatment 2013 Jul;140(1):195-205
Breast cancer research and treatment 2013 Jul;140(1):195-205
Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma.
Huang LW, Lee CC
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013 Feb;23(2):325-30
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2013 Feb;23(2):325-30
CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms.
Soave DF, Oliveira da Costa JP, da Silveira GG, Ianez RC, de Oliveira LR, Lourenço SV, Ribeiro-Silva A
Diagnostic pathology 2013 Feb 18;8:29
Diagnostic pathology 2013 Feb 18;8:29
Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.
Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, Yamada K, Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K, Morishita Y, Ohkohchi N
Cancer science 2013 Aug;104(8):1127-34
Cancer science 2013 Aug;104(8):1127-34
Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K
Oncology 2012;82(3):168-74
Oncology 2012;82(3):168-74
In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L, Tonini G, Santini D, Cavani A, Muda AO
PloS one 2012;7(9):e43110
PloS one 2012;7(9):e43110
CD24 expression as a marker for predicting clinical outcome in human gliomas.
Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z
Journal of biomedicine & biotechnology 2012;2012:517172
Journal of biomedicine & biotechnology 2012;2012:517172
Clinical value of CD24 expression in retinoblastoma.
Li J, Li C, Yuan H, Gong F
Journal of biomedicine & biotechnology 2012;2012:158084
Journal of biomedicine & biotechnology 2012;2012:158084
Expression of adhesion, attachment and invasion markers in eutopic and ectopic endometrium: a link to the aetiology of endometriosis.
Sundqvist J, Andersson KL, Scarselli G, Gemzell-Danielsson K, Lalitkumar PG
Human reproduction (Oxford, England) 2012 Sep;27(9):2737-46
Human reproduction (Oxford, England) 2012 Sep;27(9):2737-46
P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.
Vieira AF, Ricardo S, Ablett MP, Dionísio MR, Mendes N, Albergaria A, Farnie G, Gerhard R, Cameselle-Teijeiro JF, Seruca R, Schmitt F, Clarke RB, Paredes J
Stem cells (Dayton, Ohio) 2012 May;30(5):854-64
Stem cells (Dayton, Ohio) 2012 May;30(5):854-64
Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer.
Isfoss BL, Holmqvist B, Alm P, Olsson H
Histopathology 2012 Mar;60(4):617-33
Histopathology 2012 Mar;60(4):617-33
Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J, Schmitt F
Breast (Edinburgh, Scotland) 2012 Jun;21(3):354-60
Breast (Edinburgh, Scotland) 2012 Jun;21(3):354-60
Stem cell-related markers in primary breast cancers and associated metastatic lesions.
Guler G, Balci S, Costinean S, Ussakli CH, Irkkan C, Suren D, Sari E, Altundag K, Ozisik Y, Jones S, Bacher J, Shapiro CL, Huebner K
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 Jul;25(7):949-55
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012 Jul;25(7):949-55
CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
Lin Y, Zhong Y, Guan H, Zhang X, Sun Q
Journal of experimental & clinical cancer research : CR 2012 Jul 4;31:59
Journal of experimental & clinical cancer research : CR 2012 Jul 4;31:59
Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery.
Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW
Radiation oncology journal 2012 Dec;30(4):197-204
Radiation oncology journal 2012 Dec;30(4):197-204
Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.
Wang H, Wang W, Wang X, Cai K, Wu H, Ju Q, Huang Z, Gao X
Medical oncology (Northwood, London, England) 2012 Dec;29(5):3162-8
Medical oncology (Northwood, London, England) 2012 Dec;29(5):3162-8
Identification of prognostic biomarkers for glioblastomas using protein expression profiling.
Jung Y, Joo KM, Seong DH, Choi YL, Kong DS, Kim Y, Kim MH, Jin J, Suh YL, Seol HJ, Shin CS, Lee JI, Kim JH, Song SY, Nam DH
International journal of oncology 2012 Apr;40(4):1122-32
International journal of oncology 2012 Apr;40(4):1122-32
Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expression.
Simonetti S, Terracciano L, Zlobec I, Kilic E, Stasio L, Quarto M, Pettinato G, Insabato L
Breast (Edinburgh, Scotland) 2012 Apr;21(2):165-70
Breast (Edinburgh, Scotland) 2012 Apr;21(2):165-70
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J
Journal of clinical pathology 2011 Nov;64(11):937-46
Journal of clinical pathology 2011 Nov;64(11):937-46
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.
Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY
British journal of cancer 2011 May 24;104(11):1730-8
British journal of cancer 2011 May 24;104(11):1730-8
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.
Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB
Cancer research 2011 Jun 15;71(12):4236-46
Cancer research 2011 Jun 15;71(12):4236-46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K
The Journal of clinical investigation 2011 Jul;121(7):2723-35
The Journal of clinical investigation 2011 Jul;121(7):2723-35
Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells.
Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, Daidone MG, Samonigg H, Cote RJ, Dandachi N
Applied immunohistochemistry & molecular morphology : AIMM 2011 Jan;19(1):33-40
Applied immunohistochemistry & molecular morphology : AIMM 2011 Jan;19(1):33-40
Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M
Cancer science 2011 Dec;102(12):2132-8
Cancer science 2011 Dec;102(12):2132-8
CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H, Suo Z
Ultrastructural pathology 2011 Apr;35(2):72-8
Ultrastructural pathology 2011 Apr;35(2):72-8
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M
Molecular cancer therapeutics 2010 Sep;9(9):2582-92
Molecular cancer therapeutics 2010 Sep;9(9):2582-92
CD24 is upregulated in inflammatory bowel disease and stimulates cell motility and colony formation.
Ahmed MA, Jackson D, Seth R, Robins A, Lobo DN, Tomlinson IP, Ilyas M
Inflammatory bowel diseases 2010 May;16(5):795-803
Inflammatory bowel diseases 2010 May;16(5):795-803
Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin.
Kawasaki H, Ogura H, Arai Y, Baba S, Kosugi I, Tsutsui Y, Iwashita T
Pathology international 2010 Mar;60(3):228-34
Pathology international 2010 Mar;60(3):228-34
Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma.
Sung CO, Park W, Choi YL, Ahn G, Song SY, Huh SJ, Bae DS, Kim BG, Lee JH
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010 Jun;95(3):359-64
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010 Jun;95(3):359-64
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.
Park SY, Gönen M, Kim HJ, Michor F, Polyak K
The Journal of clinical investigation 2010 Feb;120(2):636-44
The Journal of clinical investigation 2010 Feb;120(2):636-44
ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients.
Hostettler L, Zlobec I, Terracciano L, Lugli A
World journal of gastroenterology 2010 Feb 14;16(6):732-9
World journal of gastroenterology 2010 Feb 14;16(6):732-9
CD24 and galectin-1 expressions in gastric adenocarcinoma and clinicopathologic significance.
Bektas S, Bahadir B, Ucan BH, Ozdamar SO
Pathology oncology research : POR 2010 Dec;16(4):569-77
Pathology oncology research : POR 2010 Dec;16(4):569-77
CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Yang XR, Xu Y, Yu B, Zhou J, Li JC, Qiu SJ, Shi YH, Wang XY, Dai Z, Shi GM, Wu B, Wu LM, Yang GH, Zhang BH, Qin WX, Fan J
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5518-27
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5518-27
Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium.
Kim KH, Choi JS, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW, Kim SH
Histology and histopathology 2009 Mar;24(3):309-16
Histology and histopathology 2009 Mar;24(3):309-16
CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T, Kuwano H
Annals of surgical oncology 2009 Feb;16(2):506-14
Annals of surgical oncology 2009 Feb;16(2):506-14
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C
Breast cancer research : BCR 2008;10(3):R53
Breast cancer research : BCR 2008;10(3):R53
The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas.
Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, Nakopoulou L
Human pathology 2008 Jul;39(7):1096-102
Human pathology 2008 Jul;39(7):1096-102
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA
Proceedings of the National Academy of Sciences of the United States of America 2008 Apr 15;105(15):5774-9
Proceedings of the National Academy of Sciences of the United States of America 2008 Apr 15;105(15):5774-9
Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.
Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH
Annals of surgical oncology 2007 Oct;14(10):2748-58
Annals of surgical oncology 2007 Oct;14(10):2748-58
CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C
Virchows Archiv : an international journal of pathology 2007 Jan;450(1):59-64
Virchows Archiv : an international journal of pathology 2007 Jan;450(1):59-64
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Oct 1;12(19):5615-21
Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Oct 1;12(19):5615-21
Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.
Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Sep 15;11(18):6574-81
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Sep 15;11(18):6574-81
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G, Pilarsky C, Wissmann C, Kaiser S, Bruemmendorf T, Roepcke S, Dahl E, Hinzmann B, Specht T, Pervan J, Stephan C, Loening S, Dietel M, Rosenthal A
The Journal of pathology 2005 Feb;205(3):359-76
The Journal of pathology 2005 Feb;205(3):359-76
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M
The Prostate 2004 Feb 1;58(2):183-92
The Prostate 2004 Feb 1;58(2):183-92
CD24 expression is a new prognostic marker in breast cancer.
Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4906-13
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4906-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of CD24 was performed by loading 25 µg of MCF-7 (Lane 1) and BAF-3 cell lysates (Lane 2) onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked with a blocking buffer at 4ºC overnight. The membrane was probed with a CD24 monoclonal antibody (Product # MA5-11833) at a dilution of 1:100 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at 35 kDa in MCF-7cell lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human ovarian carcinoma stained with CD24 antibody using Ultravision streptavidin and AEC chromogen. Note staining of apical surface of tumor cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CD24 (green) showing staining in the membrane of MCF-7 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a CD24 monoclonal antibody (Product # MA5-11833) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CD24 (green) showing staining in the membrane and cytoplasm of BAF-3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a CD24 monoclonal antibody (Product # MA5-11833) in 3% BSA-PBS at a dilution of 1:20 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CD24 (green) showing staining in the membrane and cytoplasm of Ramos cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a CD24 monoclonal antibody (Product # MA5-11833) in 3% BSA-PBS at a dilution of 1:20 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a fluorescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.